Why Groupon, CenturyLink, and Chelsea Therapeutics Jumped Today

Thursday was another up-and-down day for the stock market, but these shares were red hot. Find out more about what made these three stocks soar.

May 8, 2014 at 8:05PM

On Thursday, investors paid close attention to whether the stock market would rise to new record highs, as the final big push of earnings season included positive reports from some major companies. Yet in the end, broader concerns about the sustainability of the economic recovery, both in the U.S. and across the globe, held major-market benchmarks back. Still, Groupon (NASDAQ:GRPN), CenturyLink (NYSE:CTL), and Chelsea Therapeutics (NASDAQ:CHTP) climbed nicely, although some reasons they rose weren't necessarily the best news that shareholders could hope to hear.

Source: Groupon.

Groupon gained 6%, but the move was largely a bounce after the daily deals and online-retail company's shares plunged more than 20% yesterday. Good results from retailers' April sales data might have had a positive impact on Groupon's e-commerce sites, and with many Internet stocks hit hard in recent weeks, a pause throughout the sector led to some upward moves for many sector favorites. Nevertheless, Groupon still faces the big challenge of going beyond its landmark daily deals service to build a lasting presence in the online retail world. With so many big competitors, Groupon will have an uphill battle to execute its turnaround strategy successfully.


Source: Wikimedia Commons.

CenturyLink also rose about 6% as the telecom company announced its first-quarter results. Revenue was flat, and adjusted earnings fell 13% from the year-ago period, showing the ongoing challenges that CenturyLink faces in keeping its customers from defecting to competitors. Yet even as CenturyLink saw 120,000 phone-line customers disappear, it added 66,000 broadband Internet users and 24,000 television viewers during the quarter. CenturyLink also cited rising demand from its enterprise customers. With most telecom and cable companies seeking to maximize their exposure to small business and enterprise customers who need and can afford premium service offerings, CenturyLink needs to keep striving to get maximum market share on that front.

Chelsea Therapeutics soared 32% as the small biotech got a buyout bid from a Danish pharmaceutical company. Lundbeck priced its offer at a 29% premium to yesterday's closing price, but Chelsea Therapeutics shares actually climbed above the cash component of the buyout because of contingent value rights that it would receive after the deal closes. The contingent value rights are tied to the performance of Chelsea's Parkinson's disease treatment Northera, which treats low blood pressure and recently gained FDA approval. Given the demand for approved drugs, Lundbeck might well have gotten Chelsea Therapeutics at a bargain price here.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information